Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 19, 2020 07:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)

On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020 Plans to host virtual R&D day to review etigilimab development...
September 29, 2020 07:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update

On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020 Enrolment resumed in Phase 2 study of alvelestat in Alpha-1 Antitrypsin Deficiency and initiated...
September 24, 2020 07:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta

LONDON and REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused...
September 16, 2020 08:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma to Announce Interim Financial Results for the Six Months Ended June 30, 2020 and Host Conference Call on September 29, 2020

LONDON and REDWOOD CITY, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused...
August 25, 2020 07:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease

LONDON and REDWOOD CITY, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on...
June 30, 2020 07:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development

LONDON and REDWOOD CITY, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on...
June 16, 2020 07:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019

LONDON and REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on...
June 04, 2020 07:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Announces Completion of $70 Million Private Placement

LONDON and REDWOOD CITY, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) today announces the completion of a $70 million (£56 million) private placement...
March 27, 2020 08:00 ET | Source: Mereo BioPharma Group plc

Business Update and Directorate Change

LONDON and REDWOOD CITY, Calif., March 27, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on...
February 28, 2020 07:00 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Announces Positive Feedback from Type B End-of-Phase 2 Meeting with the FDA and Outlines Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta

LONDON and REDWOOD CITY, Calif., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," a clinical stage biopharmaceutical company focused on...